First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Part of paid clinical trials in Sarasota, Florida.
- Sponsor
- Daiichi Sankyo
- Study ID
- NCT05875168
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- DS-3939a — DRUGOne IV infusion Q3W on Day 1 of each 21-day cycle
Study Details
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Key Dates
- Start date
- Aug 18, 2023
- Status verified
- Apr 2026
- Primary completion
- Oct 20, 2026
- Completion
- Feb 15, 2027
Study Design
- Enrollment
- 540 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dose Escalation (Part 1)Participants with locally advanced, metastatic, or unresectable tumors who will receive an intravenous (IV) infusion of DS-3939a.
- Experimental: Dose Expansion (Part 2)Multiple expansion cohorts targeting various advanced solid tumors.
Primary Outcome Measure
Number of Participants with Dose-limiting Toxicities Following Treatment With DS-3939a [ Time Frame: Approximately 3 months after first dosing ]
Central Contacts
- (US Sites) Daiichi Sankyo Contact for Clinical Trial Information908-992-6400
- (Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information+81-3-6225-1111 (M-F 9-5 JST)
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Principal Investigator |
| Oregon Health & Science University | Portland | Oregon | 97239 | - |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | Principal Investigator |
| University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | - |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | Principal Investigator |
| The Medical College of Wisconsin, INC | Milwaukee | Wisconsin | 53226 | - |
Find similar trials in Sarasota, FL
By research site
Florida Cancer Specialists· Sarasota, FLOregon Health & Science University· Portland, ORRhode Island Hospital· Providence, RIUniversity of Texas M.D. Anderson Cancer Center· Houston, TXHuntsman Cancer Institute, University of Utah· Salt Lake City, UTThe Medical College of Wisconsin, INC· Milwaukee, WI
Related Studies
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPHASE1/PHASE2 · Recruiting · Novartis Pharmaceuticals · Atlanta, Georgia
- Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant TumorsPHASE1/PHASE2 · Recruiting · Daiichi Sankyo · Los Angeles, California
- Evaluate the Safety and Clinical Activity of HH2853PHASE1/PHASE2 · Recruiting · Haihe Biopharma Co., Ltd. · Phoenix, Arizona
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California